AR129012A1 - Derivados de piridazina fusionados - Google Patents

Derivados de piridazina fusionados

Info

Publication number
AR129012A1
AR129012A1 ARP230100862A ARP230100862A AR129012A1 AR 129012 A1 AR129012 A1 AR 129012A1 AR P230100862 A ARP230100862 A AR P230100862A AR P230100862 A ARP230100862 A AR P230100862A AR 129012 A1 AR129012 A1 AR 129012A1
Authority
AR
Argentina
Prior art keywords
pyridazine derivatives
fused pyridazine
formula
compounds
fused
Prior art date
Application number
ARP230100862A
Other languages
English (en)
Spanish (es)
Inventor
Mark E Adams
Jason W Brown
Edcon Chang
Mingnam Tang
Holger Monenschein
Kristin Schleicher
Huikai Sun
Feng Zhou
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR129012A1 publication Critical patent/AR129012A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP230100862A 2022-04-07 2023-04-05 Derivados de piridazina fusionados AR129012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263328709P 2022-04-07 2022-04-07

Publications (1)

Publication Number Publication Date
AR129012A1 true AR129012A1 (es) 2024-07-03

Family

ID=86329425

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100862A AR129012A1 (es) 2022-04-07 2023-04-05 Derivados de piridazina fusionados

Country Status (6)

Country Link
US (1) US20250340563A1 (https=)
EP (1) EP4504733A1 (https=)
JP (1) JP2025511819A (https=)
AR (1) AR129012A1 (https=)
TW (1) TW202345838A (https=)
WO (1) WO2023194964A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
TW202319055A (zh) * 2021-07-21 2023-05-16 日商安斯泰來製藥股份有限公司 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2022135567A1 (zh) * 2020-12-25 2022-06-30 上海拓界生物医药科技有限公司 一类含哒嗪的化合物及其医药用途
TW202319055A (zh) * 2021-07-21 2023-05-16 日商安斯泰來製藥股份有限公司 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物

Also Published As

Publication number Publication date
WO2023194964A1 (en) 2023-10-12
JP2025511819A (ja) 2025-04-16
TW202345838A (zh) 2023-12-01
US20250340563A1 (en) 2025-11-06
EP4504733A1 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
AR129012A1 (es) Derivados de piridazina fusionados
CO2024016875A2 (es) Compuestos de pirido[4,3-d]pirimidina
MX2021013135A (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.
AR127050A1 (es) Compuestos espirocíclicos
CO4650038A1 (es) Derivados del indazol sustituidos y compuestos relacionados
CO2025011205A2 (es) Derivados de 1-amino-4-fenilftalazina útiles para el tratamiento de enfermedades neurodegenerativas
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
AR119910A1 (es) DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL
PA8437301A1 (es) Derivados de indazol
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
MX2024011697A (es) Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de proteinas que contienen el dominio de pirina de la familia de los receptores similares al dominio de oligomerizacion de union a nucleotido 3 (nlrp3)
ECSP22082217A (es) Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida
AR036094A1 (es) Compuestos derivados de acido sulfonico, composicion farmaceutica y su uso en la preparacion de medicamentos
CL2025002805A1 (es) Derivados de amida para inhibir nlrp3 y usos de estos.
AR131705A1 (es) Derivados de 1-amino-4-fenilftalazina
CL2024002101A1 (es) Proceso de elaboración de derivados de morfolinas sustituidas
CO2021017202A2 (es) Compuestos tricíclicos
JOP20250053A1 (ar) البلورات المشتركة من مشتقات 4-بيرازولوبيريدين-6-يل]-5-ميثيل-تريازول-1-يل]بيبريدين-1-كربونتريل مع حمض الجاليك والنيكوتيناميد
MX2024010321A (es) Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos
CO2025014993A2 (es) Derivados bicíclicos semisaturados y usos relacionados
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
CL2022003067A1 (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
CO2025010159A2 (es) Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo
CL2024003257A1 (es) Compuestos heteroaromáticos bicíclicos condensados y su uso en el tratamiento del cáncer
AR118471A1 (es) Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2

Legal Events

Date Code Title Description
FB Suspension of granting procedure